Suppr超能文献

阴茎癌的分子特征:新预后标志物和潜在治疗靶点的文献综述

[Molecular characterization of penile cancer : Literature review of new prognostic markers and potential therapeutic targets].

作者信息

May M, Brookman-May S D, Ecke T H, Burger M

机构信息

Urologische Klinik, Klinikum St. Elisabeth Straubing, St. Elisabeth-Str. 23, 94315, Straubing, Deutschland.

Urologische Klinik, Ludwigs-Maximilians-Universität (LMU) München, München, Deutschland.

出版信息

Urologe A. 2018 Apr;57(4):398-407. doi: 10.1007/s00120-018-0596-4.

Abstract

Squamous cell carcinoma of the penis (SCCP) is a rare cancer type in Western industrialized nations; nevertheless, it shows an aggressive course of disease in advanced tumor stages with accordantly high recurrence and progression rates. While molecular biomarkers are not established in clinical routine for the management of SCCP patients yet, the accordant unmet need is enormous, as adequate biomarkers would be meaningful for prognostic determination, planning of modality and extent of primary therapy, indication for inguinal lymph node resection, adjuvant treatment, and as potential targets for specific systemic treatment. SCCP regularly develops from a precursor lesion. In this regard, human papillomavirus (HPV)-dependent and -independent pathways are differentiated. The potential for specific target therapy options is mainly based on the decoding of genetic and epigenetic signatures of distinct molecular pathways. In order to develop targeted and personalized treatment strategies based on molecular pathways, an increase in translational research in large multi-institutional collaborations must be promoted. This review article aims to summarize the current status of research concerning molecular changes related to SCCP under separate consideration of prognostic molecular markers, on the one hand, and biomarkers considered potential therapeutic targets, on the other hand. In addition, previous research activities of our own working group on this topic are briefly described.

摘要

阴茎鳞状细胞癌(SCCP)在西方工业化国家是一种罕见的癌症类型;然而,在晚期肿瘤阶段,它呈现出侵袭性的病程,复发率和进展率相应较高。虽然分子生物标志物在临床常规中尚未用于SCCP患者的管理,但相应的未满足需求巨大,因为合适的生物标志物对于预后判定、原发治疗方式和范围的规划、腹股沟淋巴结切除的指征、辅助治疗以及作为特定全身治疗的潜在靶点都具有重要意义。SCCP通常由前驱病变发展而来。在这方面,可区分人乳头瘤病毒(HPV)依赖性和非依赖性途径。特定靶向治疗方案的潜力主要基于对不同分子途径的遗传和表观遗传特征的解码。为了基于分子途径制定靶向和个性化的治疗策略,必须促进大型多机构合作中的转化研究。这篇综述文章旨在一方面单独考虑预后分子标志物,另一方面考虑被视为潜在治疗靶点的生物标志物,总结与SCCP相关的分子变化的研究现状。此外,还简要描述了我们自己的工作组此前在该主题上的研究活动。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验